NTRA News and Press, Natera Inc. From 07/02/21

New Results From the Landmark Prospective CIRCULATE Trial Expand Clinical Utility of the Signatera® MRD Test in Colorectal Cancer Data presented in oral session at the 2021 ESMO GI Congress shows >99% of MRD-negative patients were recurrence-free at 6 months of follow-up...

Natera, Inc. is a leading global diagnostics company developing cell-free DNA ("cfDNA") tests focusing on women's health, oncology, and organ health. Natera's current diagnostics product offering includes ~10 different unique tests with most of the product revenues coming from th...

Natera (NASDAQ: NTRA) has quietly grown its market cap by more than 875% in the past five years, trouncing the 103% gains of the S&P 500 over that time frame. The $10.25 billion med-tech company, which honed its diagnostics craft on non-invasive blood testing to screen for fetal...

Natera ([[NTRA]] +0.4%) and BGI Genomics announces the launch of the BGI/Natera Signatera Assay in China.The company's Signatera assay has been utilized in numerous clinical studies across non-small cell lung, bladder, breast and colorectal cancers, to identify molecular r...

Natera and BGI Genomics Announce Commercial Launch of the BGI/Natera Signatera Assay in China The formal launch of the BGI/Natera Signatera Assay is the next step towards achieving global access to personalized ctDNA testing PR Newswire AUSTIN, Texas and SHENZH...

4 Top Health Care Stocks To Add To Your Watchlist This Week Health care stocks have been in focus in the stock market over the past year for obvious reasons. Everyone was taken aback as we were plagued by the global pandemic. However, every crisis presents a new opportunity. Fun...

Natera Awarded Advanced Diagnostic Laboratory Test (ADLT) Status for its Signatera® MRD Test From CMS PR Newswire AUSTIN, Texas , June 18, 2021 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today an...

Nature Journal Publishes Prospective, Randomized Study Validating Signatera® for Prediction of Immunotherapy Benefit Landmark study is first to definitively show that the Signatera MRD test can identify bladder cancer patients likely to benefit from immunotherapy after surg...

Personalized technology aims to address both early- and advanced-stage cancer monitoring applications Foundation Medicine, Inc. and Natera, Inc. (NASDAQ: NTRA), today announced the launch of the research use version of FoundationOne®Tracker, Foundation Medicine&...

Natera Announces New Prospera™ Data at the ATC 2021 Virtual Connect Conference PR Newswire AUSTIN, Texas , June 4, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it wi...